Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

NCT06968806 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Aortic Dissection
Inflammation

Interventions

DRUG: Ketorolac
DRUG: 0.9 % saline

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]